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MEXICAN-AMERICAN COHORT AND 
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Advisory Professor: Xifeng Wu, M.D., Ph.D. 
 
I. SOCIAL-DEMOGRAPHICS, HEALTH BEHAVIORS, AND TELOMERE 
LENGTH IN MEXICAN AMERICANS: A COHORT STUDY 
Recent studies using a prospective cohort design have suggested that telomere length in 
peripheral blood leukocytes is not only a potential indicator of cellular aging that has 
been linked to stressful life experience and health behaviors, but also a prognostic marker 
for major chronic diseases; however, such study has never been done among adult 
Mexican Americans. In this current study, we examined cross-sectional associations 
among social-demographics, lifestyle behaviors, and relative telomere length (RTL) in 
peripheral blood leukocytes, as well as longitudinal relationships among major chronic 
diseases, weight gain, and RTL, among 12,792 Mexican Americans aged 20 to 85 years 
in the Mano-A-Mano, a Mexican American Cohort. As expected, RTL was inversely 
correlated with age (ρ=-0.15, p<0.001). In the multivariate analysis, we found that RTL 
was positively correlated with levels of education (P=0.021), self-insurance (P=0.041), 
body mass index (BMI) (P<0.001), and sleeping time per day (P for trend<0.001). In 
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contrast, RTL was inversely correlated with sitting time per day (P for trend =0.001). In 
longitudinal analysis, we found that longer RTL was modestly but positively associated 
with increased risks of diabetes (adjusted hazard ratio (adj.HR) =1.04, 95% conference 
interval (CI) =1.01-1.08) and hypertension (adj.HR=1.03, 95% CI=1.00-1.08). Similar 
but marginal association was observed for incident cancer (adj.HR=1.04, 95% 
CI=0.99-1.10). Further stratified by cancer site, the significant association was observed 
for lung cancer (adj.HR=1.21, 95% CI=1.00-1.46). In addition, longer RTL was a 
positive predictor of at least 10% weight gain (adj.HR=1.03, 95% CI=1.00-1.05). In 
summary, our results in Mexican Americans support the notion that telomere length is a 
biological mechanism by which social demographics and health behaviors “get under the 
skin” to affect health.  
II. METHYLATION IN SERUM CELL-FREE DNA AND CPG-SNP WITH 
BLADDER CANCER RISK 
Epigenetic alterations are early events of cancers, including bladder cancer. In the present 
study, we aimed to examine methylation profiles of circulating DNA in serum of bladder 
cancer patients, in an effort to develop reliable DNA methylation signatures to diagnose 
the disease. Firstly, we performed whole genome DNA methylation profiling with 
Illumina Infinium HumanMethylation450 beadchip in 23 participants in a bladder cancer 
case control study. 396 target cytosine-phosphate- guanine (CpG) sites were identified as 
hypermethylated in cases compared with the controls. The top 5 candidate CpG sites 
hypermethylated in cases during the screening phase were further validated by 
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pyrosequencing, in 100 bladder cancer patients (including 50 non-muscle invasive and 50 
muscle invasive bladder cancers) and 50 healthy controls. Successful methylation data 
were obtained for 4 of the selected CpG sites, located in genes of TTC23, WWOX, 
ZNF624 and LOC2211122, respectively. Unfortunately, none of these 4 sites exhibited 
differential methylation between cases and controls in this validation.  Interestingly, 
there was a SNP rs8038732 (G>A) in the methylation site of gene TTC23. The GG 
genotype showed near complete methylation, G/A heterozygotes half methylation, and 
AA complete loss of methylation. This SNP is clearly a functional SNP because the G>A 
transition almost completely knocks out methylation at this site.  It would be interesting 
to see whether this SNP affect bladder cancer risk. However, this SNP was not genotyped 
in our previously published genome-wide association study (GWAS). But, we found that 
another SNP, rs1377267 (A>C), on the GWAS chip is in strong linkage disequilibrium 
(r2=0.85) with rs8038732. Moreover, the SNP rs1377267 significantly associated with 
the risk of bladder cancer in our GWAS study. Specifically, the heterozygous alleles (AC) 
was associated with higher bladder cancer risk (OR=1.34, 95% CI=1.09-1.65), whereas 
the homozygous alleles (CC) were marginally associated with lower risk of bladder 
cancer (OR=0.78, 95% CI= 0.59-1.03). From this result, we could infer that rs8038732 
has similar association with the risk of bladder cancer. Our study suggests that rs8038732 
affects the risk of bladder cancer by removing a cytosine-phosphate-guanine (CpG) 
dinucleotide and knocking out DNA methylation at this site. Loss of methylation may 
increase the expression of TTC23, which is a potential oncogene. 
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Project I: Social-demographics, health behaviors and telomere length in Mexican 
Americans：a cohort study 
Introduction 
Telomeres consist of tandem DNA repeats and associated proteins that cap the 
end of chromosomes and provide protection to eukaryotic chromosomes [1] [2]. As a 
normal cellular aging process, telomere length decreases with age. However, how quick 
telomeres shorten varies significantly among the population, and many factors, including 
genetic, environmental, socio-demographic, cultural and behavioral factors [3-5], may 
affect the rate of telomere length shortening. More importantly, how long the telomeres are 
has significant public health and disease implication. Critically short telomeres may lead to 
chromosomal instability and thus cause diseases [6]. On the other hand, cells with longer 
telomeres may have prolonged cell life and higher chances of developing DNA damage 
and chromosomal instability, thus being at high risk of tumorigenesis [7]. Current studies 
have demonstrated links between telomere length and risk of major chronic diseases, 
including cancer [8-10], type 2 diabetes [11], and cardiovascular disease [12, 13].  
 
The link between low socioeconomic status (SES) and the development of 
age-related chronic diseases has been widely observed [14-20]. Several theories have been 
proposed and the common assumption is that the chronic stress associated with social 
disadvantage causes wear and tear on the body, which promotes the declined rate of 
physiological function [20, 21]. Such decline may affect leukocyte telomere length and 
14 
 
further impact biological aging and other age-related chronic diseases. Studying the role of 
leukocyte telomere length in stress, biological aging, and age-related chronic diseases is 
particularly relevant to Mexican Americans. Mexican Americans are one of the 
fastest-growing populations in U.S. [22].  Compared to non-Hispanic whites, Mexican 
Americans tend to have lower SES, including lower income and homeownership, and less 
education and access to health care [23]. On the other hand, Mexican Americans are 
experiencing high burden of age-related chronic diseases, including cardiovascular 
diseases and type 2 diabetes [24-27]. In addition, they have unique psychological, somatic, 
and social stress associated with acculturation [28, 29]. Studies have shown that 
acculturation confers risk for stress, and stress related diseases and poor health behaviors in 
Mexican Americans [30-32].  
 
Leukocyte telomere length may also be the link between unhealthy behaviors and 
age-related chronic diseases [3, 33, 34]. Maintaining a healthy lifestyle, including keeping 
a normal weight, regular physical activity, not smoking, and not heavy drinking, can 
contribute to decrease the levels of inflammation and oxidative stress [34-38], which helps 
to prevent chronic diseases [33, 34, 39, 40]. Studying health behaviors, age-related chronic 
diseases, and leukocyte telomere length is particularly important for Mexican Americans 
because 3 out of 4 Mexican Americans are either overweight or obese [41, 42]. In addition, 
they participate in low levels of physical activity [43], and recent surveillance data show 
only 44.6% met national physical activity recommendations [44].  
15 
 
To date, the relationship among social demographics, lifestyle behaviors, and 
leukocyte telomere length has not been investigated in any prospective cohort study of 
adult Mexican Americans. Here, taking advantage of a large ongoing prospective Mexican 
American Cohort study, we detected relative telomere length (RTL) in peripheral blood 
leukocytes from 12,792 Mexican American study subjects, and investigated its 
relationships with social demographics, lifestyle behaviors, and major chronic diseases at 
baseline, and with the development of cancer, diabetes, and hypertension at follow-up. 
Additionally, we studied whether RTL could predict prospective weight gain during 
follow-up.   
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METHODS AND MATERIALS 
Study Population  
The samples for the current study were recruited from participants in a large 
population-based cohort of Mexican origin households recruited from Houston [45]. This 
Mano a Mano cohort, an ongoing prospective cohort of 1st and 2nd generation Mexican 
origin immigrant households in Houston, TX, initiated in July 2001 and maintained by 
the Department of Epidemiology at the University of Texas MD Anderson Cancer Center 
in Houston, Texas. A detailed description of the sampling and recruitment strategy has 
been published previously [46]. Briefly, Participants was drawn by random-digit-dialing, 
block walking in predominantly Mexican American neighborhoods, from community 
centers and local clinics, or networking through currently enrolled participants [47] [48]. 
Once the identified eligible households agreed to participate in the study, then the written 
informed consent would be obtained; the participants were interviewed by well-trained 
interviewers using a structured questionnaire; the interview last ~45 minutes and was 
conducted in Spanish or English; the epidemiological data collected by this questionnaire 
included birthplace, residential history, social-demographic characteristics, lifestyle 
behaviors, levels of physical activity, personal medical history, family history of chronic 
disease, acculturation, and occupation exposure [49]. All the participants were followed 
up through telephone annually; the study was approved by the institutional review board 
of MD Anderson Cancer Center [46]. 
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Relative Telomere Length (RTL) Assessment  
Genomic DNA was isolated from participants’ whole blood with the QIAamp 
Maxi DNA kit from Qiagen (Valencia, CA). Isolated DNA samples were quantiﬁed by 
Quant-iTTM PicoGreen®dsDNA Reagent and Kits from Invitrogen (Carlsbad, CA) 
according to the manufacturer’s directions. The RTL was measured with a modified 
method of real-time quantitative polymerase chain reaction (PCR), which was originally 
set up by Cawthon [50, 51]. A detailed description of the experimental strategy has been 
published previously [52-54]. Briefly, the ratio of the telomere repeat copy number (T) to 
the single gene (human globulin) copy number (S) was detected, which was proportional 
to the telomere length [54]. The mixture of PCR reaction (14 µl) consisted of 1 x SYBR 
Green Master Mix (Applied Biosystems, Foster City, CA), 200 nmol/l Tel-1 primer 
(5’-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT), 200 nmol/l Tel-2 
primer (5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT), and 5 ng 
genomic DNA; the PCR reaction mixture (14 µl) for HGB gene amplification was similar 
except the primers- Hgb-1 primer (5’-GCTTCTGACACAACTGTGTTCACTAGC) and 
Hgb-2 primer (5’-CACCAA CTTCATCCACGTTCACC); the thermal cycling conditions 
were 1 cycle at 95oC for 10 minutes followed by 40 cycles at 95oC for 15 seconds and at 
56oC (for telomere amplification) or 58oC (for HGB amplification) for 1 minute; the 
HT7900 system (Applied Biosystems, CA) was used to perform the Real-time PCR，each 
sample was detected in duplicates in a 384-well plate; in each assay, negative control, 
positive control (Roche Applied Science, Pleasanton, CA), calibrator DNA, and a 
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standard curve were included; the standard deviations for the Ct values were set at 0.25 
for all the samples; the standard curve with high coefficient of determination (R2≥0.99) 
will be selected for further analysis; in addition, the acceptable coefficient of variation 
were <3% for intra-assay and <5% for the inter assay [53]. 
 
Statistical Analysis  
We used the statistical software package SAS, version 9.4 (SAS, Cary, NC) for 
analysis. Although the relative telomere length data were not normally distributed, we 
performed the analysis using both data with and without log transformation. We found 
there was no significant difference in estimate of the relationships among 
social-demographics, health behaviors, major chronic diseases, and RTL. Thus, only data 
without log transformation were presented here. Differences in the distribution of 
social-demographics, health behaviors, and major chronic diseases were evaluated by 
Pearson χ2 test for categorical variables. Spearman correlation was used to assess the 
relationship between age and RTL. In the univariate analysis, the general linear 
regression analysis was used to compare RTL by the selected variable. Both age and 
gender were adjusted as appropriate. Mediation analysis was performed to assess the role 
of RTL between BMI and chronic diseases at baseline. In the multivariate analysis, the 
general linear model was used. The social-demographic and health behavior variables 
with P value less than 0.25 in the univariate analysis were included in the multivariate 
analysis. For joint effect analysis, we created a social-behavioral score by including 2 
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SES related variables (education and self-insurance) and 2 lifestyle behaviors (sitting 
time and sleeping time). For each variable, we created a binary high SES or healthy 
variable, defined as at least high school education, having self-insurance, sitting less than 
2 hours per day, and sleeping more than 6 hours per day, respectively. The 
social-behavioral score ranged from 0 (low SES and no healthy behaviors) to 4 (high SES 
and healthy behaviors). Multivariate analysis was used to assess the correlation between 
the social behavior and RTL. The associations among incident cancer, diabetes, 
hypertension and RTL were assessed using the multivariable-adjusted Cox 
proportional-hazard regression model. RTL was analyzed as both a continuous and 
categorical variable. For categorical variable, cutoff points were set at the quartile values 
in the non-cancer study population. Adjusted Hazard ratio (HR) and 95% confidence 
interval (CI) were estimated and co-variants were adjusted as appropriate. 
Multivariable-adjusted Cox proportional-hazard regression model was also used to 
examine whether RTL at baseline could predict at least 10% weight gain in the follow-up. 
All statistical tests were 2-sided, and the value of statistical significance was set as 0.05. 
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RESULTS 
A total of 12,792 MA study subjects were included in the RTL analysis. Among 
them, 614 were excluded for further analysis due to abnormal RTL value (outside of ±3 
standard deviation of age adjusted mean RTL). Thus, a total of 12,178 study subjects 
were included in further data analysis. Baseline social demographic characteristics, 
immigration related variables, lifestyle factors, and major chronic diseases are presented 
in Table 1. The mean and median ages of the population were 42 and 39 years old, 
respectively. The majority of study subjects were women (79.56%) and married (or living 
together) (77.00%). In this study, we used levels of education, health insurance, home 
and vehicle ownership to assess SES. Only 40.60% of study subjects had at least high 
school education. For health insurance, 49.66%, 46.23%, and 68.55% had self, partner, 
and kids insurances, respectively. In terms of home and vehicle ownership, 45.96% and 
78.41% owned a home and a vehicle, respectively. For immigration related variables, the 
majority was born in Mexico (73.77%) and less acculturated (63.28%). Among Mexico 
born study subjects, 29.53% arrived in U.S. younger than 20 years old and 46.39% have 
lived in U.S. for more than 15 years. We included 6 lifestyle behaviors in the analysis, 
namely cigarette smoking, alcohol consumption, BMI, sedentary behavior, sitting time, 
and sleeping time. The majority of study subjects were overweight or obese (85.04%), 
never smokers (71.80%), never alcohol drinkers (66.66%), and sedentary (79.06%). Over 
a half of study subjects had more than 2 hours sitting time per day (53.42%). The 
majority of study subjects had 7 to 8 hours sleeping time per day (60.36%). The most 
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prevalent chronic disease was hypertension (19.48%), followed by diabetes (15.27%), 
gallbladder disease (8.83%), asthma (3.97%), cancer (2.65%), and kidney disease 
(1.91%).  
 
The mean and median of RTLs were 0.76 and 0.75, respectively. The range was 
between 0.21 and 0.99. As expected, a significant inverse relationship between RTL and 
age was observed (ρ=-0.15, p<0.001). For every one year increase in age, there was a 
0.002 reduction in RTL. In the univariate analysis, we investigated the relationships 
among baseline social-demographics, health behaviors, major chronic diseases, and RTL 
(Table 1).  
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Table 1. Distribution of selected socio-demographics, health behaviors, and major diseases and 
RTL among 12,178 Mexican American study subjects 
Variables Number of study subjects (%) 
Relative telomere 
length  P value* 
Age at enrollment 
   20-31 3,116 (25.59) 0.81 
 32-39 3,104 (25.49) 0.78 
 40-50 2,925 (24.02) 0.75 
 >50 3,033 (24.91) 0.72 <0.001 
Gender 
   Men 2,535 (20.44) 0.76 
 Women 9,866 (79.56) 0.76 0.324 
Marital Status 
   Married/living as 
married 9,365 (77.00) 0.76 
 Other 2,797 (23.00) 0.76 0.780 
Education 
   <High school 7,229 (59.40) 0.76 
 At least high school 4,941 (40.60) 0.77 0.069 
Self insurance 
   Yes 5,498 (49.66) 0.77 
 No 5,574 (50.34) 0.76 0.004 
Partner insurance 
   Yes 4,227 (46.23) 0.77 
 No 4,917 (53.77) 0.76 0.189 
Kids insurance 
   Yes 6,502(68.55) 0.77 
 No 2,983(31.45) 0.76 0.264 
Own home 
   Yes 5,025 (45.96) 0.76 
 No 5,909 (54.04) 0.76 0.539 
Own car 
   Yes 8,558 (78.41) 0.76 
 No 2,356 (21.59) 0.77 0.618 
Birth location 
   Mexico 8,973 (73.77) 0.76 
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U.S. 3,191 (26.23) 0.76 0.221 
Years lived in U.S. (for born in Mexico only) 
<5 1,038 (11.57) 0.75 
 5-10 1,841 (20.52) 0.77 
 10-15 1,930 (21.51) 0.76 
 >15 4,162 (46.39) 0.77 0.255 
Age at arrival (for born in Mexico only) 
<20  2,649 (29.53) 0.76 
 20-29 3,906 (43.55) 0.77 
 ≥30 2,415 (26.92) 0.76 0.242 
Language acculturation 
   High 4,449 (36.72) 0.76 
 Low 7,666 (63.28) 0.76 0.308 
Cigarettes smoking status 
   Current 1,579 (12.99) 0.76 
 Former 1,848 (15.20) 0.76 
 Never 8,727 (71.80) 0.76 0.882 
Alcohol drinking status 
   Current 2,770 (22.88) 0.76 
 Former 1,267 (10.46) 0.76 
 Never 8,071 (66.66) 0.77 0.244 
BMI 
   Under/Normal weight (<25) 1,791 (14.96) 0.75 
 Overweight (25-29.9) 4,072 (34.00) 0.76 
 Obese (>30) 6,112 (51.04) 0.77 <0.001 
Sedentary behavior 
   No 2,380 (20.94) 0.77 
 Yes 8,987 (79.06) 0.76 0.052 
Sit hours/day 
   <2 4,784 (46.58) 0.76 
 2-3 2,817 (27.43) 0.74 
 >3 2,670 (26.00) 0.75 <0.001 
Sleep hours/day 
   <=6 3,307 (28.96) 0.74 
 7-8 6,894 (60.36) 0.75 
 ≥9 1,220 (10.68) 0.77 0.001 
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Any Major Disease (prevalence) 
   Yes 7,298 (60.01) 0.77 
 No 4,864 (39.99) 0.75 0.013 
High blood pressure 
(prevalence) 
   Yes 2,372 (19.48) 0.78 
 No 9,805 (80.52) 0.76 <0.001 
Diabetes (prevalence) 
   Yes 1,859 (15.27) 0.77 
 No 10,317 (84.73) 0.76 0.401 
Gallbladder disease 
(prevalence) 
   Yes 1,075 (8.83) 0.79 
 No 11,102 (91.17) 0.76 0.001 
Asthma (prevalence) 
   Yes 483 (3.97) 0.77 
 No 11,694 (96.03) 0.76 0.729 
All cancer (prevalence) 
   Yes 323 (2.65) 0.84 
 No 11,855 (97.35) 0.76 <0.001 
Kidney disease (prevalence) 
   Yes 232 (1.91) 0.82 
 No 11,945 (98.09) 0.76 0.014 
* Adjust for age and gender as appropriate 
 
Among demographic characteristics, the most significant association was observed for 
age category. As expected, we observed a significant trend of decreasing RTL with the 
increasing age category from 20-31 to over 50 years old (p<0.001). Among SES related 
variables, study subjects who had less than high school education had marginally shorter 
RTL than those who had at least high school education (p=0.069). Study subjects who 
had self-insurance had significantly longer RTL than those who did not (p=0.004). No 
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significant association was observed between immigration related variables (including 
birth location, acculturation, years lived in U.S., and age at arrival) and RTL.  
 
For health behaviors, the most significant association was with BMI. We found a 
significant positive relationship between BMI (as continuous variable) and RTL 
(p<0.001). In the BMI categorical analysis, after adjusting for age and gender, RTL was 
shortest among study subjects who were under or normal weight (0.75), median among 
those who were overweight (0.76), and longest among those who were obese (0.77) 
(p<0.001). When the study subjects were stratified by age categories, 20-29, 30-39, 40-49, 
50-59, 60-69, 70-79, and 80 or more years old (Figure 1), the trend of RTL difference 
among BMI categories was persistent for most of the age categories. More interestingly, 
when we further compared the rate of RTL shortening by age among three BMI 
categories, RTL shortening by age was seemingly quicker among those who were under 
or normal weight than those who were overweight or obese, although the difference of 
slope was not statistically significant (p=0.187). When we compared RTL difference 
between those in 20-29 and those in 80 or more years old, the difference was 0.19 for 
under or normal weight, 0.13 for overweight, and 0.085 for obese groups (P=0.005). 
Significant relationships were also observed for sitting time and sleeping time. Study 
subjects who had less than 2 hours sitting time per day had the longest RTL (0.76) 
compared to those who had 2-3 hours (0.74) and more than 3 hours sitting time per day 
(0.75) (P<0.001). RTL was positively associated with hours of sleeping per day. RTL 
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was longest among those who slept at least 9 hours per day (0.77), median among those 
who slept 7-8 hours per day (0.75), and shortest among those who slept no more than 6 
hours per day (0.74) (P<0.001). In addition, those who were sedentary had marginally 
shorter RTL than those who were not sedentary (0.76 vs 0.77, P=0.052).  
 
      
Fig. 1 Association of RTL and BMI in different age categories 
 
For major chronic diseases at baseline, study subjects who had at least one of six major 
chronic diseases (including hypertension, diabetes, gallbladder disease, asthma, cancer, 
and kidney disease) had longer RTL than those who have no chronic diseases (RTL: 0.77 
vs 0.75, p=0.013). When stratified by type of chronic disease, significant difference was 
remained for hypertension (P<0.001), gallbladder disease (P<0.001), cancer (P<0.001), 
and kidney disease (P=0.014). In the mediation analysis, we examined the potential 
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mediating role of RTL on the association between BMI and major chronic diseases. The 
significant effect was observed for hypertension and gallbladder disease. About 5.25% of 
the association between BMI and hypertension, and 5.13% of the association between 
BMI and gallbladder disease were mediated by RTL (P=0.001 and 0.037, respectively).  
 
Next, we included all social-demographics and health behaviors with p value ≤ 
0.25 in the univariate analysis (from Table 1) into a multivariate model. The results were 
presented in Table 2. BMI, as a continuous variable, was positively associated with RTL 
(P<0.001). Compared to study subjects with lower education level, those with at least 
high school education had significantly longer RTL (P=0.021). Compared to those who 
slept 6 or less hours per day, those who slept 7-8 and more than 8 hours had significantly 
longer RTL (P=0.003 and 0.001, respectively). RTL was also longer among those who 
had self-insurance than those who had no self-insurance (P=0.041). On the other hand, 
RTL was significantly inversely associated with age (P<0.001), and RTL was shorter 
among those who sat more than 3 hours per day than those who sat less than 2 hours per 
day (P<0.001).   
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Table 2. Multivariate regression analysis of RTL on social-demographics and health behaviors 
Variables Estimate Standard Error P value 
age -0.003 0.0002 <0.001 
Gender (women vs men) 0.002 0.008 0.804 
BMI 0.002 0.0005 <0.001 
Education (≥ high school vs < high school) 0.013 0.006 0.021 
Birth place (U.S. vs Mexico) 0.009 0.007 0.197 
Ever vs never smokers -0.008 0.007 0.230 
Ever vs never drinkers 0.009 0.007 0.220 
Sleep time (≤6 hours/day)    
7-8 hours/day 0.028 0.009 0.003 
≥9hours/day 0.039 0.010 0.001 
Sitting time (<2 hours/day)    
2-3 hours/day -0.003 0.008 0.674 
>3 hours/day -0.026 0.007 <0.001 
Sedentary lifestyle (yes vs no) -0.0003 0.007 0.965 
Self-insurance  (yes vs no) 0.012 0.006 0.041 
Intercept 0.838 0.021 <0.001 
R2 0.026   
 
To assess the potential joint effect of SES and health behaviors on RTL, we 
created a social-behavioral score by including 2 SES related variables (education and 
self-insurance) and 2 lifestyle behaviors (sitting time and sleeping time). For each 
variable, we created a binary high SES or healthy variable, defined as at least high school 
education, having self-insurance, sitting less than 2 hours per day, and sleeping more than 
6 hours per day, respectively. The social-behavioral score ranged from 0 (low SES and no 
healthy behaviors) to 4 (high SES and healthy behaviors). We investigated the association 
between the social-behavioral score and RTL (Figure 2). In general, with the score 
increased from 0 to 4, RTL gradually increased (p<0.001). For study subjects with 
social-behavioral score 0, 1, 2, 3, and 4, their mean RTL was 0.71, 0.73, 0.75, 0.77, and 
0.78, respectively.     
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Fig. 2 Association between the social-behavioral score and RTL 
 
To assess whether RTL was a predictor of chronic diseases, we analyzed the relationships 
between RTL and incident cancer, diabetes, and hypertension during the follow-up. A 
total of 287 incident cancer cases were observed and confirmed during the follow-up. 
Overall, RTL was not significant different between incident cancer cases and non-cancer 
controls (0.77 V.S. 0.76, p=0.555). In the multivariable-adjusted Cox proportional-hazard 
regression model, using RTL as a continuous variable, we found that longer RTL was 
marginally associated with increased risk of overall cancer (adjusted HR=1.04, 
95%CI=0.99-1.10) (Table 3).   
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Table 3. Risk of incident cancer associated with RTL 
RTL  
(continuous variables, unit=0.1) 
Cancer Cases Non-cancer 
controls 
Adj. HRs (95% CI)* P value 
All cancer 287 10,340 1.04 (0.99-1.10) 0.111 
Breast cancer (women only) 68 8,414 1.01 (0.91-1.12) 0.867 
Lung cancer 18 10,605 1.21 (1.00-1.46) 0.049 
Cervical cancer (women only) 11 8,465 0.96 (0.76-1.23) 0.766 
Liver cancer 12 10,611 1.01 (0.78-1.31) 0.960 
Prostate cancer (men only) 20 2,120 1.09 (0.86-1.36) 0.898 
All Cancer 
By quartile N (%) N (%) Adj. HRs (95% CI)* P Value 
1st 71 (24.74) 2,615 (25.29) reference 
 2nd  90 (31.36) 2,760 (26.69) 1.15 (0.84-1.58) 0.372 
3rd 72 (25.09) 2,468 (23.87) 1.20 (0.86-1.67) 0.279 
4th 54 (18.82) 2,497 (24.15) 1.41 (1.00-2.03) 0.049 
P for trend 
   
0.064 
*adjusted for age, obesity status, alcohol drinking, cigarette smoking, and education.  
 
 
When stratified by top incident cancer site, the only significant association observed was 
with lung cancer (adjusted HR=1.21, 95% CI=1.00-1.46). In further quartile analysis, 
compared to individuals who had shortest RTL (1st quartile), those who had longer RTL 
(2nd, 3rd, and 4th quartiles) had an increased risk of overall cancer. However, the only 
significant association was observed among those in the 4th quartile with the highest RTL 
(adjusted HR=1.41, 95% CI=1.00-2.03). The p for trend was 0.064. During the follow-up, 
a total of 648 and 878 study subjects were diagnosed with diabetes and hypertension. 
Overall, RTL was significantly positively associated with risks of incident diabetes and 
hypertension (diabetes: adjusted HR=1.04, 95% CI=1.01-1.08; hypertension: adjusted 
HR=1.03, 95% CI=1.00-1.06) (Table 4). 
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Table 4. Risk of incident diabetes and high blood pressure associated with RTL  
RTL Diabetes 
N (%) 
Non-diabetes 
N (%) 
HR(95%CI) P value 
quartile     
1st 152 (23.46) 2,075 (24.82) ref.  
2nd  211 (32.56) 2,165 (25.89) 1.23 (1.00-1.53) 0.055 
3rd 144 (22.22) 2,025 (24.22) 1.00 (0.79-1.26) 0.988 
4th 141 (21.76) 2,096 (25.07) 1.31 (1.03-1.67) 0.026 
P for trend    0.167 
Continuous variable (unit=0.1)  1.04(1.01-1.08) 0.021 
 High blood 
Pressure N (%) 
No high blood 
Pressure N (%) 
  
quartile     
1st 227 (25.85) 1,931 (25.14) ref.  
2nd 257 (29.27) 1,985 (25.84) 0.93(0.77-1.11) 0.422 
3rd 217 (24.72) 1,828 (23.80) 0.93(0.77-1.13) 0.474 
4th 177 (20.16) 1,937 (25.22) 1.22(1.01-1.50) 0.044 
P for trend    0.123 
Continuous variable (unit=0.1)  1.03(1.00-1.06) 0.049 
 *adjusted for age, sex, obesity status, alcohol drinking, and education.   
 
 
In further quartile analysis, we found that study subjects who had the longest RTL (4th 
quartile) had a 1.31-fold increased risk of diabetes (adjusted HR=1.31, 95% CI=1.03-1.67) 
compared to those who had shortest RTL (1st quartile). Similarly, we observed that study 
subjects who had highest RTL (4th quartile) had 1.22 fold increased risk of hypertension 
(adjusted HR=1.22, 95%CI=1.01-1.50) compared to participants who had lowest RTL (1st 
quartile). Last, in a subset of study subjects with multiple weight data during follow-up, 
we explored whether RTL could predict weight gain during the follow-up (Table 5).  
  
32 
 
Table 5. Risk of weight gain(>=10%) and RTL   
  HR(95%CI) P value* 
age 0.97 (0.97-0.98) <0.001 
Gender: women vs men 1.49 (1.17-1.91) 0.001 
BMI 0.95 (0.94-0.96) <0.001 
marital status:  married vs other 0.73 (0.63-0.85) <0.001 
acculturation: high vs low 1.20 (1.02-1.41) 0.026 
Birth place: U.S. vs Mexico 0.83(0.69-1.00) 0.049 
RTL (0.1 per unit) 1.03 (1.00-1.05) 0.035 
 
Using at least 10% weight gain compared to the baseline weight during the follow-up  
as the event, we performed multivariate regression analysis. The significant variables in 
the final model included age at baseline, gender, baseline BMI, marriage status, 
acculturation, birth place, and RTL. RTL was a positive predictor of at least 10% weight 
gain during the follow-up (adjusted HR=1.03, 95%CI=1.00-1.05). In addition, older age, 
married (or living together), high BMI, and born in U.S. were associated with less likely 
to gain at least 10% weight (age: adjusted HR=0.97, 95%CI=0.97-0.98; marriage status: 
adjusted HR=0.73, 95%CI=0.63-0.85; BMI: adjusted HR=0.95, 95%CI=0.94-0.96; and 
birth place: adjusted HR=0.83, 95%CI=0.69-1.00, respectively). Being women and 
higher acculturated were associated with more likely to gain at least 10% weight (gender: 
adjusted HR=1.49, 95% CI=1.17-1.91; and acculturation: adjusted HR=1.20, 95% 
CI=1.02-1.41).    
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Discussion 
The associations among social-demographics, health behaviors, and telomere 
length have rarely been studied in adult Mexican Americans. The only published study 
was from the National Health and Nutrition Examination Survey (1999-2002), which 
includes 1,377 Mexican Americans [20]. In that study, the only significant factor 
correlated with RTL was age. In our current study, with 12,792 Mexican Americans aged 
20 to 85 years, in the cross-sectional analysis, we found that lower SES (measured by low 
education levels and without self-insurance) was significantly associated with shorter 
RTL. In addition, we observed RTL was positively correlated with BMI, sleeping time, 
and several major chronic diseases, and negatively correlated with age and sitting time. 
Then, in the longitudinal analysis, we found longer RTL was a predictor for all cancer, 
diabetes, hypertension, and weight gain, although the associations were modest to 
marginal.        
 
Socioeconomic disparities in chronic diseases are well-documented, but little is 
known about the mechanisms [20]. In the current study, we use indicators of SES 
including education attainment, health insurance, home and vehicle ownership. We 
observed an inverse relationship between levels of SES and RTL. Study subjects with 
less than high school education had shorter RTL than those who had at least high school 
education (P=0.021). Similarly, study subjects with no self-insurance had shorter RTL 
than those who had self-insurance (P=0.041). We did not find a significant association 
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between home and vehicle ownership and RTL. Our results are consistent with several 
previous studies. For example, Needham et al. found that telomere length was positively 
associated with education level (P<0.01) [20]. However, the significant relationship was 
only observed among Caucasian American study subjects, not among African and 
Mexican Americans. The only significant relationship reported among Mexican 
Americans was from Multi-Ethnic Study of Atherosclerosis (MESA), which evaluated 
the relationship between SES and telomere length among 963 U.S. adolescents, including 
510 Mexican American adolescents [20, 55]. In that study, telomere length was found 
negatively associated with current home ownership and father’s education [20].  
 
Health behavior is a major determinant of chronic disease risk in most of the developed 
countries [33, 34, 39, 56]. Epidemiological and basic science studies have shown that 
unhealthy lifestyle including cigarette smoking, heavy drinking, sedentary behavior, and 
obesity could increase stress levels, decrease immune function, and deteriorate 
physiological condition [57-62]. In the current study, we found inverse relationships 
among sitting time, sleeping time, and RTL, and a positive relationship between BMI and 
RTL. No significant relationship was observed among cigarette smoking, alcohol 
drinking, sedentary behavior, and RTL. The relationship among sedentary behavior, 
sitting time, and RTL has been investigated previously [6, 20, 63-70]. The results are still 
limited and inconsistent. For example, Sjögren et al. found   sitting time was associated 
with longer telomere in sedentary, overweight 68-year-old participants [70]. Using data 
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from Nurses’ Health Study, Du et al. reported that sitting time and sedentary behavior 
were not associated with leukocyte telomere length [6]. However, they found that longer 
telomeres are associated with moderate to vigorous amounts of physical activity [6]. 
Much of the discrepancy among different studies may be due to differences in study 
population, such as race, age, occupation, and sample size.  
 
One intriguing but puzzling finding from this study is the positive relationship 
between BMI and telomere length. In a recent systematic review and meta-analysis of 29 
existing studies, Muezzinler et al. concluded an inverse association between BMI and 
RTL in adults [71]. However, in the Genetic Epidemiology Research Study on Adult 
Health and Aging (GERA) with 100,000 study subjects presented in 2012 American 
Society of Human Genetic Annual meeting, Schaefer et al. reported that BMI was 
positively correlated with telomere length in saliva DNAs, which is consistent with our 
finding. To eliminate the potential age effect, we stratified the study subjects based on 
their age categories, and we found study subjects in the obese group had steadily longest 
telomere length and those in the normal weight group had consistently shortest telomere 
length. More interestingly, the difference of telomere length by BMI status was becoming 
larger with the age increased. In studying the relationship between RTL and perspective 
weight gain, we found that long RTL was associated with higher likelihood of gaining at 
least 10% weight compared to the baseline. Our observation is consistent with the results 
from the Health ABC study, in which Njajou et al. reported that telomere length was 
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positively associated with both % body fat and BMI in 7- year follow-up [72]. Clearly, 
more work is still needed to study the underlying molecular mechanisms between BMI 
and RTL.  
 
The relationship between RTL and major chronic diseases (both prevalent and 
incident) was another piece of interesting finding. In cross-sectional analyses, longer RTL 
was associated with increased prevalence of overall major chronic diseases as well as 
several individually, including hypertension, gallbladder disease, cancer, and kidney 
disease. In prospective analyses, longer RTL was associated with modestly to marginally 
increased risks of diabetes, hypertension, overall cancer, and lung cancer. The 
relationship between RTL and cancer has been studied extensively in both case control 
and cohort settings [9, 10, 54, 73-87]. However, the results are inconsistent. One of the 
exceptions might be lung cancer. In a recent pooled analysis, Seow et al. found that 
telomere length was positively associated with higher risk of lung cancer [87]. Findings 
were consistent across the three cohorts, PLCO trial, ATBC trial, and SWHS. Our result 
is consistent with those findings. Although we do not know the exact biological 
explanation, upon exposure to carcinogens, cells with longer telomeres may be less likely 
to enter senescence or apoptosis. Their survival could increase their chance to have 
extended carcinogen exposure and thereby increase the risk of developing genetic 
abnormalities.  
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However, the relationship among diabetes, hypertension, and RTL is puzzling. In 
a recent meta-analysis study, Zhao et al. found that shortened telomere length was 
significantly associated with an increased risk of type 2 diabetes (OR=1.29, 95% CI: 
1.11-1.14) [11]. Similar association was also observed between shortened telomere length 
and risk of hypertension [88]. One limitation in our study is that the incident diabetes and 
hypertension cases were self-reported and we did not separate type 1 from type 2 diabetes. 
Therefore misclassification may somehow contribute to the discrepancy. In addition, the 
observed associations in our study are modest at best. Apparently, more studies are 
needed to further clarify the associations.  
 
There are several limitations in this study. First, the number of incident cancer, 
diabetes, and hypertension is still small, especially for cancer. This limits our statistical 
power to detect the associations. Thus, we need to be very cautious to interpret our 
findings. Second, the analysis of SES and health behavior in relation to RTL is 
cross-sectional. The findings do not tell us the timing of the effect. Longitudinal data 
would be necessary to analyze the rate of telomere shortening. Finally, the exposure of 
stress was not directly assessed [20]. 
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Conclusion 
The relationships among SES, health behavior, chronic diseases and telomere length have 
been studied previously [3, 33]. However, such study has never been comprehensively 
investigated among adult Mexican Americans. This study fills the gap. Among 12,792 
Mexican Americans, we found that RTL is significantly affected by SES and health 
behavior. In addition, we found longer RTL is a predictor of lung cancer, diabetes, 
hypertension and weight gain. Together with the results of other studies in different 
populations and different races, our study suggests that RTL is one mechanism by which 
social conditions and health behaviors affect human health.   
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Project II: Methylation in serum cell-free DNA and CpG-SNP with bladder cancer 
risk 
INTRODUCTION 
Bladder cancer has the fifth highest incidence rate of all malignancies in the 
United States, with high recurrence rates [89-91]. In most cases, bladder cancer appears 
as a non–muscle-invasive urothelial carcinoma [92]. Early detection of bladder cancer is 
critical for increased chance of bladder preservation and improved overall survival. 
Biomarkers play an important role in the early detection as they are the early events in the 
tumorigenesis [93]. The ideal biomarker must be reliable, inexpensive, minimally 
invasive, specific and sensitive to the disease [93, 94]. We are interested in developing 
blood-based markers for the early detection of bladder cancer. 
 
Circulating cell free DNA 
The presence of tumor DNA in circulating blood (plasma or serum) has been 
documented dating back to 1977 [95]. Cell-free DNA (cfDNA) was thought to be 
released from either apoptotic or necrotic cancer cells, from direct secretion or as a 
byproduct of phagocytosis from macrophages or other scavenger cells [95, 96]. With 
recent advances in next generation sequencing (NGS) technology, cfDNA has been 
explored extensively for its potential application to cancer detection [97]. In general, the 
studies of cfDNA as cancer biomarkers focus on monitoring the presence of methylation, 
aberrant tumor DNA mutation, microsatellite alternations, and mitochondria DNA in 
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blood circulation [96, 97]. In this current study, we are going to focus on aberrant 
methylation in circulating cell free DNAs. 
 
DNA Methylation 
In general, DNA methylation is thought to be an early event in tumorigenesis and 
has therefore been proposed as a potential early cancer detection marker [98, 99]. To date, 
accumulating data have shown that DNA methylation could be used to evaluate cancer 
risk [100-102], predict patients’ prognosis [91, 101-103], and evaluate the response to 
chemotherapeutic drugs [102, 104]. Mostly, DNA methylation occurs at a cytosine in a 
CpG dinucleotide, by adding a methyl group to the number 5 carbon of the cytosine 
pyrimidine ring [105]. Aberrant DNA methylation has been associated with 
tumorigenesis as a consequence of the alteration it causes in gene expression [98, 106]; 
with hypermethylation associated with gene s, and hypomethylation with gene activation 
[107]. Meanwhile, DNA methylation detection is relatively easy due to PCR-based 
methods, which can compensate for the low content limitation [93], suggesting that 
methylation of circulating DNA may become a biomarker for cancer diagnosis [93, 94, 
105]. 
 
CpG-SNP 
single-nucleotide polymorphisms in CpG sites are referred as CpG-SNPs. About 
34% of the C/T or G/A autosomal SNPs identified by the second-phase HapMap database 
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are located within a CpG site [105, 108], and some of these CpG SNPs have been related 
with diseases [105, 109-112]. CpG-SNP would be a potential molecular mechanism 
through which SNPs influence a phenotype of disease [105].  
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METHODS AND MATERIALS 
Study design 
An outline of the study design is shown in Figure 3. Firstly, whole-genome serum 
DNA methylation profiling was performed using the Infinium HumanMethylation450 
BeadChip array (Illumina). 23 samples were included (15 cases and 8 controls) in the 
screening. We found 396 significantly hypermethylated  CpG sites in cases and selected 
the top 5 for validation by pyrosequencing in 150 samples (50 controls, 50 non-muscle 
invasive and 50 muscle invasive bladder cancer patients). 
 
 
Fig. 3 Flow chart of the study design  
 
Study population and epidemiologic data  
The study population has been described elsewhere [52, 113-115]. Briefly, the 
population consisted of patients with newly diagnosed and histopathologically confirmed 
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bladder cancer accrued at the University of Texas MD Anderson Cancer Center and 
Baylor College of Medicine. The Controls were healthy individuals without a prior 
history of cancer (except nonmelanoma skin cancer) [116], which were selected from a 
large control pool recruited through a collaboration with the Kelsey-Seybold Clinic, the 
largest private multi-specialty physician group in Houston [117]. Informed consents were 
obtained from all the participants before collection of epidemiologic data and blood 
samples. Epidemiologic and demographic data were collected through in-person 
interviews by trained MD Anderson interviewers. All subjects were interviewed with a 
structured questionnaire [118]. All studies were approved by the Institutional Review 
boards of MD Anderson, Baylor College of Medicine, and Kelsey-Seybold Clinic [119]. 
 
Sample collection 
All study participants signed informed consent and underwent an in-person 
interview by trained MD Anderson staff with a structured questionnaire that elicited 
information on epidemiologic data, including demographic characteristics, medical 
history and smoking history [120]. Immediately after each interview, a 40-mL peripheral 
blood sample was drawn. About 10 ml was drawn into a red top serum-separating tube, 
processed for serum extraction within 2 hours, and then transferred into liquid nitrogen 
tanks for long-term storage [120]. 
 
Circulating cell-free DNA Isolation 
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Cell-free circulating DNA was extracted from 1 ml of the serum with QIAamp 
Circulating Nucleic Acid Kit from Qiagen (Hilden, Germany) according to the 
manufacturer’s instructions. The final elution volume was 20 µl and extracted DNA was 
quantified by NanoDrop ND-1000 spectrometer (Thermo Scientific, DE).  
 
Bisulﬁte treatment of DNA 
For samples used in chip screening, DNA was treated by bisulfite using EZ DNA 
Methylation Kit (Zymo Research, Orange, CA) following the manufacturer’s protocol. In 
brief, 1 µg of DNA was treated with sodium bisulfite, through which all unmethylated 
cytosines were converted to uracils, but leaving methyl-cytosines unaltered; after 
purification, the cfDNA obtained was dissolved in 10 µl of TE buffer and this modified 
DNA was quantified by NanoDrop ND-1000 spectrometer (Thermo Scientific, DE); the 
efficiency of cfDNA recovery after bisulfite treatment was around 55% [121]. After 
bisulfite conversion, each sample was amplified, fragmented by enzymes, and hybridized 
to the Illumina Infinium HumanMethylation450 BeadChip [122]. 
 
For samples analyzed by pyrosequencing, 800 ng of genomic DNA was 
bisulfite-treated with EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA) 
according to the manufacturer’s protocol. To improve the efficiency of DNA elution, the 
purification columns were stored overnight in M-Elution Buffer at 4oC prior to 
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centrifugation. The samples were eluted in 40 µl of M-Elution Buffer, and 2 µl 
(equivalent to 25 ng of bisulfite-modified DNA) was used for each PCR reaction.  
 
Whole-Genome DNA methylation Profiling  
Whole-genome serum DNA methylation profiling was performed on 23 serum 
samples (15 bladder cancer patients and 8 controls) using the Infinium 
HumanMethylation450 BeadChip (Illumina) according to the manufacturer’s standard 
protocols. This BeadChip covers more than 485,000 methylation sites, located in 99% of 
RefSeq genes distributed across the promoter, UTR regions, first exon and gene body, 
and 3’-UTR regions [122, 123]. Samples were bisulfite converted using the EZ DNA 
methylation kit according to the manufacturer’s protocol. Controls on the array were used 
to track the bisulfite conversion efficiency. The Infinium® HumanMethylation450 
BeadChip array (Illumina Inc., San Diego, CA) was used to measure genome-wide CpG 
methylation levels using beads with specific probes designed to target individual CpG 
sites on bisulfite-converted genomic DNA [124].  
 
Methylation analysis with pyrosequencing  
The subsequent pyrosequencing analysis was done at the DNA Methylation 
Analysis Core, The University of Texas MD Anderson Cancer Center. Primers of 
pyrosequencing PCR and sequencing for the individual CpG sites were designed for the 
forward strand with Pyromark Assay Design SW 1.0 software (Qiagen, Hilden, 
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Germany), the reverse primer was biotin labeled at the 5’- end [125]. The primer 
sequences are shown in Table 6. 
Table 6 Information of Pyrosequencing PCR and sequencing primers  
Oligo Name Sequence 5' to 3' Sequence to analyze PCR 
Product 
Size (bp) 
CG26853071/
F1 
GAGGTTGGTTTAGTGGAAGTAAT TGGGGYGTTGYGGAAGTTTTTG
GGTAGAAA ATGAAA 
141 
CG26853071/
Rbio2 
[Btn]AACAATTTTCATTTTCTACCCAA
AAACTTC 
  
CG26853071/
S3 
AGTTAGTTTTTGTTAATTTTGTGT   
CG05276469/
F1 
GTTAGGTTGTTTTAGGGATTGG YGTAGTTTTTTGTYGG 113 
CG05276469/
Rbio2 
[Btn]CCCCCCAACTAACCCTACCCA   
CG05276469/
S3 
TTGTTTAGAGGGGTTTAG   
CG01630032/
F1 
GTGTTTGAGATTAAGATTTATTTGGT
AAGT 
TAGGYGAGTGGAGGGGAGTTT
TGTTAGGTA 
177 
CG01630032/
Rbio2 
[Btn]AACAAAACTCCCCTCCACT   
CG01630032/
S3 
AAAGTAGAAATTAATTTTAATGATT   
CG25576961/
F1 
TTAGTTTATTGTGTAAAATGTGGTTA
GAG 
GGGYGGGGGAGA 208 
CG25576961/
Rbio2 
[Btn]AACCCCATCTACCACCTAAACTC
TTACA 
  
CG25576961/
S3 
GAGGTTAGGATTAGTGG   
1. Forward primer for pyrosequencing PCR 
2. Reverse prime with biotin label for pyrosequencing PCR 
3. Sequencing primer 
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A sequencing primer is identified within 1 to 5 base pairs near the CpG site of 
interest, with an annealing temperature of 40 ± 5 oC. After that, forward and reverse 
primers are identified upstream and downstream to the sequencing primer, with a target 
annealing temperature ranging from 50 oC to 60 oC and amplicon product size ranging 
from 100bp to 200bp.  Gradient PCR was used to detect the optimal annealing 
temperatures for these primers. Controls for high methylation (SssI-treated DNA), low 
methylation (WGA-amplified DNA), partial methylation (equimolar mixture of 
SssI-treated and WGA-amplified DNA) and no-DNA template were included in each 
reaction. For regions that were composed of mostly A and T bases, and additional control 
of WGA-amplified DNA that was subsequently SssI-treated prior to bisulfite conversion 
was also included, to account for biased representation of those regions in the whole 
genome amplified genome.  
PCR reactions were performed in a total volume of 15 µl, which was used for the 
following pyrosequencing reaction (Table 7, 8). This method was previously described 
[126]. In brief, streptavidin-sepharose high-performance beads (GE Healthcare Life 
Sciences, Piscataway, NJ) were used to purify the PCR product. In addition, 
co-denaturation of the biotin-labeled PCR products and sequencing primer was 
performed following the guide of  PSQ96 sample preparation. Sequencing was 
conducted on a PSQ HS 96 system (Biotage AB, Uppsala, Sweden) with the reagents of 
PyroMark Gold Q96 CDT (Qiagen, Hilden, Germany) according to the manufacturer’s 
48 
 
instructions. The methylation level was calculated using the Pyro-Q CpG 1.0.9v software 
(Biotage AB, Uppsala, Sweden) [126]. 
 
  Table 8 PCR Cycling conditions 
Step Temp (oC) Duration 
1 95 10 m 
2 95 30 s 
3 53 30s 
4 72 30s 
5 Repeat (steps 2-4) 44 times (or 49 times, for CG6961)   
6 72 7 m 
7 12 infinite 
 
 
Identification of proxy SNPs  
The analysis of proxy SNP was done by SNAP (SNP annotation and proxy) 
search [127] [30]. The search was based on genotype data released by the 1000 Genomes 
project and International HapMap Project. Inclusion criteria for LD (linkage 
disequilibrium) SNPs were set as an r2 threshold >0.8 from pairwise LD calculations and 
a distance limit of 500 kb from the query SNP [105]. 
Table 7. System of PCR reaction 
PCR Reaction Volume (µL) 
Bisulfite DNA 2 
2x Zymo Reaction Buffer 7.5 
dNTP Mix (25mM each) 0.15 
F primer (10uM) 0.3 
R primer (10uM) 0.3 
Zymo Taq 0.12 
ddH2O 4.63 
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Genotyping 
The method of genotyping has been described before [115]， the primary screen 
was performed using the Illumina HumanHap 610 chip.  
 
Statistical Analysis 
Bead Studio Methylation Module software (Illumina) was used to analyze the 
different methylation levels among different samples and groups [128]. The STATA 
software (STATA Corp., College Station, TX) was used for all the statistical analyses. 
Student’s t- test was used to assess differences in DNA methylation levels between cases 
and controls. Differences in host characteristics between cases and controls were assessed 
by X2 test for categorical variables (sex, smoking status, etc.) and the Student’s t test for 
continuous variables (age). Unconditional multivariate logistic regression was performed 
with adjustment for covariates to calculate odds ratios and 95% confidence intervals (CI). 
All P values were two-sided, and the significance cut-off point was set as 0.05.  
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RESULTS 
Whole genome DNA methylation profiling 
In our study, circulating cell free DNA from serum samples of 23 patients (7 
NMIBC, 8 MIBC, and 8 healthy controls) were used for whole-genome methylation 
profiling with Illumina Infinium HumanMethylation450 beadchip array. The methylation 
statuses of more than 485,000 CpG sites were assessed. Prior to further analyses, probes 
failed in any one of the 23 samples and probes in sex chromosomes were removed [128] 
. As described before [129, 130], probes with β values being ≤0.2 or ≥0.8 in all 
samples were also excluded [128]. As a result, we got 275,054 probes for the further 
analysis, and obtained huge amount of CpG sites differentially methylated in bladder 
cancer patients compared with the healthy controls. Thus, we tried to narrow down the 
candidates by selecting those sites that were significantly hypermethylated in cases with 
∆β> 0.2 (∆β=βcase-βcontrol). As a result, we got 396 candidate CpG sites which are 
hypermethylated in cases compared with the healthy controls. 
 
Validation of hypermethylated CpG sites by pyrosequencing  
Five out of the hypermethylated 396 CpG sites from the microarray (Table 9) 
were selected for validation by bisulfite modification-based pyrosequencing assays in 150 
serum samples (50 NMIBC, 50 MIBC, and 50 Controls). The characteristics of 
participants were summarized in Table 10.  
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Table 9 Five CpG sites are hypermethylated in cases in the screening  
Target ID Gene Symbol DNA Methylation Level ( β value) P value 
Case (N=15) Control(N=8) 
Δβ=Case β -Control β 
 
Mean(SD) Mean (SD)   
cg26853071 LOC221122 0.72 (0.08) 0.40 (0.30) 0.32 0.005 
cg20823859 OVGP1 0.56(0.17) 0.27 (0.17) 0.29 0.001 
cg25576961 TTC23 0.38(0.17) 0.11 (0.05) 0.27 0.001 
Cg05276469 ZNF624  0.59(0.12) 0.38(0.19) 0.21 0.003 
cg01630032 WWOX 0.54(0.07) 0.34(0.07) 0.20 0.005 
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Table 10. Host characteristics of participants in validation by pyrosequencing 
 
Variables 
Overall     Cases   
 
Case (n=100) 
Control 
(n=50) 
p  
 
NMIBC 
(n=50) 
MIBC (n=50) p  
Age (y) 
       
     Mean(SD) 68.81( 8.51) 68.94( 8.13) 0.929 
 
68.40( 9.11) 69.22( 7.92) 0.632 
 
n (%) n (%) 
  
n (%) n (%) 
 
Gender 
       
     Male 90(90.00) 45(90.00) 
  
45(90.00) 45(90.00) 
 
     Female 10(10.00) 5(10.00) 1 
 
5(10.00) 5(10.00) 1 
smoking status 
       
     Never 25(25.00) 20(40.00) 
  
12(24.00) 13(26.00) 
 
     Ever 75(75.00) 30(60.00) 0.059 
 
38(76.00) 37(74.00) 0.817 
Death 
       
     Yes 
    
7(14.00) 10(20.00) 
 
     No 
    
43(86.00) 40(80.00) 0.424 
Recurrence 
       
     Yes 
    
18(36.00) 1(2.00) 
 
     No 
    
32(64.00) 49(98.00) <0.001 
Progression 
       
     Yes 
    
15(30.00) 5(10.00) 
 
     No 
    
35(70.00) 45(90.00) 0.012 
Treatment 
       
     iBCG 
    
21(42.00) 
  
     mBCG 
    
29(58.00) 
  
     TUR+cystectomy 
    
7(14.00) 
 
    TUR+cystectomy+chemotherapy     14(28.00)  
     TUR+chemotherapy 
    
6(12.00) 
 
     TUR 
     
4(8.00) 
 
     Others 
 
        19(38.00)   
Successful DNA methylation data were generated for 4 of the 5 CpG sites, located 
in genes of WWOX, LOC2211122, ZNF624 and TTC23 (Figure 4). For these 4 CpG 
sites, all the data passed the quality controls built into the analysis. 
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Fig. 4 Successful DNA methylation data were generated for 4 of the 5 CpG sites 
There were two methylation sites in gene ZNF624, both of which were 
hypomethylated (Figure 5), so we used the average of methylation levels at the two sites 
for each sample for analysis.  
 
Fig. 5 Distribution of methylation levels of gene ZNF624 in different methylation sites 
For gene WWOX, there is a SNP in the methylation site with a minor allele 
frequency (MAF) less than 0.01, which was ignored. In addition, there is a SNP 
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rs8038732 (G>A) with an MAF more than 0.42 in the methylation site of gene TTC23. 
The minor allele (A allele) would cause differential methylation by eliminating the CpG 
site, so the samples were grouped and analyzed according to the genotype of rs8038732. 
Unfortunately, none of these 4 sites exhibited differential methylation between cases and 
controls in our validation (Table 11, 12) 
Table 11. Association of methylation levels of candidate target genes and bladder cancer 
Gene  Methylation % 
  
Methylation % 
 
 
Cases (N=100) Control(N=50) 
 
 
NMIBC (N=42) MIBC (N=42) 
 
 
Mean (SD) Mean (SD) P 
 
Mean (SD) Mean (SD) P 
WWOX 43.31 (22.5) 41.45 (21.27) 0.656 
 
43.24 (21.58) 43.39(23.59) 0.976 
ZNF624 5.45 (1.92) 5.34 (1.83) 0.760 
 
5.51 (1.73) 5.4(2.11) 0.789 
LOC221112 91.11 (10.72) 91.1 (5.00) 0.995 
 
90.37(14.62) 91.85(4.18) 0.531 
 
Table 12. Association of methylation levels of TTC23 and bladder cancer 
Gene Genotype Case (n=100) control (n=50)     NMIBC (n=50)   MIBC(n=50)   
TTC23 rs8038732 
 (G>A) 
 
n 
Methy%  
Mean(SD) 
 
n 
Methy% 
Mean(SD) 
 
 p 
  
n 
Methy% 
Mean(SD) 
 
 n 
Methy%  
Mean(SD) 
 
P 
 
GG 26 91.48(4.20) 14 91.37(3.04) 0.93  16 92.95(2.28)  10 89.14(5.52) 0.055 
 
GA 53 47.67(6.80) 25 45.88(8.25) 0.313  25 46.92(9.02)  28 48.35(3.97) 0.450 
  AA 21 1.74(2.18) 11 2.41(2.47) 0.431  9 2.27(2.88)  12 1.34(1.49) 0.346 
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CpG-SNP rs8038732 and methylation level of gene TTC23 
Interestingly, the methylation level of TTC23 was associated with the genotype 
of SNP rs8038732 (G>A). As shown in Figure 6, the GG genotype showed near 
complete methylation, G/A heterozygotes half methylation, and AA genotype complete 
loss of methylation. This SNP is clearly a functional SNP because the G>A transition 
completely knocks out methylation at this site. It would be interesting to see whether this 
SNP affect bladder cancer risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
      
Fig. 6 rs8038732 affects methylation level of TTC23 
 
Association of SNP rs8038732 with bladder cancer risk in GWAS study 
SNP rs8038732 was not genotyped in our previously published genome-wide 
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association study (GWAS) [115]. However, we found that another SNP, rs1377267 (A>C), 
on the GWAS chip is in strong linkage disequilibrium (r2=0.85) with rs8038732 (Table 
13).  
Table13 rs8038732 is in high LD with rs1377267 
SNP Linked Distance R-Squared Chromosome Coordinate_HG18 
rs8038732 rs1377267 29908 0.85 chr15 97557412 
 
The SNP rs1377267 was significantly associated with bladder cancer risk in our 
GWAS study. Specifically, the OR for individuals carrying one copy of the variant allele 
(C) was 1.34 (95% CI, 1.09–1.65), and for those carrying two copies was 0.78 (95% CI, 
0.59–1.03). (Table 14)  
Table14 Association of rs1377267 and bladder cancer risk 
Genotype Case  Control OR (95% CI) P 
rs1377267(A>C) 
    
AA 306 341 1 Ref 
 
AC 528 426 1.34(1.09-1.65) 0.005 
CC 135 190 0.78(0.59-1.03) 0.086 
The association was also similar in superficial (Table 15) and invasive bladder cancer 
(Table 16). 
Table 15 Association of rs1377267 and cancer risk in NMIBC patients 
Genotype NMIBC Control OR (95% CI) P 
rs1377267 (A>C) 
    
AA 154 341 Ref 
 
AC 278 426 1.42(1.11-1.83) 0.005 
CC 65 190 0.73(0.52-1.05) 0.089 
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Table 16 Association of rs1377267 and cancer risk in MIBC patients 
Genotype MIBC Control OR (95% CI) P 
rs1377267 (A>C) 
    
AA 128 341 Ref 
 
AC 218 426 1.28(0.98-1.69) 0.06 
CC 55 190 0.76(0.52-1.11) 0.15 
 
From this result, we could infer that rs8038732 has similar association with the risk of 
bladder cancer: the heterozygous allele change (GA) increases the bladder cancer risk 
significantly. The homozygous variant genotype (AA) is protective for bladder cancer 
risk, although the association is not statistically significant. 
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DISCUSSION 
DNA methylation is one of the most common epigenetic alterations that associate 
with cancer development and progression [131]. Meanwhile, DNA methylation detection 
is relatively easy due to PCR based methods, which can compensate for the low content 
limitation, suggesting that methylation of circulating DNA may be a promising biomarker 
for cancer detection [93, 94, 128, 132]. 
 
In this study, 396 hypermethylated CpG sites were identified by Illumina 
HumanMethylation450 beadchip array. We selected 5 of the candidate CpG sites for 
individual validation by pyrosequencing. Successful methylation data were obtained for 4 
of the selected CpG sites, located in genes of TTC23, WWOX, ZNF624 and 
LOC2211122. Unfortunately, none of these 4 sites exhibited differential methylation 
between cases and controls in this validation. To date, pyrosequencing has been a method 
with high specificity for DNA methylation analysis [128]. In our study, the 
pyrosequencing was performed with 25 ng of bisulfite-modified starting DNA, and all the 
results passed the quality controls. For the whole genome DNA methylation profiling, we 
started with 1 µg circulating cell free DNA from 1 ml of serum samples. After the 
bisulfite treatment, ~250 ng bisulﬁte -converted DNA was loaded to the Illumina 
HumanMethylation450 beadchip. There might be two reasons that we could not validate 
the primary screening results. First, the data from Illumina HumanMethylation450 
beadchip array are not as accurate as pyrosequencing due to the low amount of input 
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DNA. Second, the sample size of the primary screening was small (23 samples) and there 
was high likelihood of false positives for the top statistically significant hits. It is fairly 
common that in large scale genetic and epigenetic biomarker studies, the validated 
biomarkers are not among the very top hits during the primary screening. In the future, 
we need to enlarge the sample size of primary screening and meanwhile select more 
candidate CpG sites for validation. Nevertheless, our study is the first to use Illumina 
HumanMethylation450 beadchip to profiling circulating cell free DNA, whereas previous 
studies have all used genomic DNA from tissue or peripheral blood. [124, 128, 133-135] 
Our study supports the feasibility of genome-wide CpG methylation profiling and 
validation of circulating cell-free DNA for the identification of early detection markers.  
 
Interestingly, there was a SNP rs8038732 (G>A) in the methylation site of gene 
TTC23. The GG genotype showed near complete methylation (Mean of 
Methylation%=92.6), GA heterozygotes half methylation (Mean of Methylation%=43.4), 
and AA complete loss of methylation Mean of Methylation%=1.9).  This SNP is clearly 
a functional SNP because the G>A transition completely knocks out methylation at this 
site. It was reported that altered DNA methylation could suppress tumor suppressor genes 
or activate oncogenes, thus initiate tumorigenesis and promote the progression of cancer 
[136]. Therefore, it would be interesting to see whether this SNP affects the risk of 
bladder cancer. Fortunately, we have data from our previously published GWAS of 
bladder cancer.  Even though this specific SNP was not genotyped the GWAS [115], we 
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found another SNP rs1377267 (A>C), on the GWAS chip that is in strong linkage 
disequilibrium (r2=0.85) with rs8038732. We then analyzed the associations of SNP 
rs1377267 with bladder cancer risk in the GWAS study of 969 bladder cancer cases and 
946 controls. The SNP rs1377267 turned out to be significantly associated with bladder 
cancer risk. Specifically, the heterozygous alleles (AC) was associated with higher 
bladder cancer risk (OR=1.34, 95% CI=1.09-1.65), whereas the homozygous alleles (CC) 
was marginally associated with lower risk of bladder cancer (OR=0.78, 95% CI= 
0.59-1.03). Since this SNP is highly linked with our interested SNP, we could infer that 
rs8038732 has similar association with the risk of bladder cancer. 
 
The SNP rs8038732 is located in the intron region of the TTC23 gene, which was 
reported as a proto-oncogene. The TTC23 protein was also named Cervical Cancer 
Proto-Oncogene 8 Protein. A previous paper showed that TTC23 is a functional target 
gene of the BACH1 transcription factor, which is involved in the oxidative stress 
response and in cell cycle control [137]. In our study, individuals with the GA genotype 
had half methylation and higher bladder cancer risk; but individuals with the AA 
genotype who almost completely lost methylation had reduced risk of bladder cancer. 
One potential explanation for this observation is that the carcinogenesis is promoted by 
medium expression of oncogene TTC23, whereas cell death is induced by overexpression 
of TTC23 (Figure 7).  
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Fig. 7 Potential mechanism: overexpression of TTC23 could induce cell death 
 
In general, oncogene is believed to promote carcinogenesis through increasing 
cell proliferation and survival.  However, there has been evidence showing that 
oncogenes have anti-survival characteristics and contribute to tumor suppression. For 
instance, Ras was one of the first identified human proto-oncogenes. Ras is a 
membrane-anchored protein, which plays an important role in regulating cell 
differentiation, growth and apoptosis [138-145]. A study published in 1983 found the 
expression of Ras induced growth arrest in fibroblasts, which was one of the first 
indications that Ras may have dual functions in cell growth [145, 146]. Subsequent 
studies have shown that whether Ras signaling plays either a pro-apoptotic or a 
pro-growth role depends on the balance between the selectively deactivated or activated 
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downstream pathways [145]. The active overexpression of Ras was also reported to 
induce autophagic cell death [147]. Therefore, our observation that the TTC23 may be a 
risk or protective factor for bladder cancer etiology is consistent with these previous 
observations. 
  
63 
 
CONCLUSION 
This study shows the feasibility of performing genome-wide CpG methylation 
profiling of ctDNA as a tool to screening biomarkers for bladder cancer early detection. 
A serendipitous observation was that a SNP rs8038732 in a CpG site of TTC23 is 
significantly associated with bladder cancer risk. This CpG-SNP affects local DNA 
methylation which, in turn, may affect gene expression and increase bladder cancer risk. 
Our data suggest that the abrogation of CpG dinucleotide, which is the site of DNA 
methylation, is a potential mechanism through which rs8038732 affects the risk of 
bladder cancer. 
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